These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12955370)

  • 61. Correlation between proguanil and metabolites in plasma and saliva.
    Alexander C; Nathwani D; Zimbler N; Taylor RB
    J Antimicrob Chemother; 1995 Dec; 36(6):1113-5. PubMed ID: 8821621
    [No Abstract]   [Full Text] [Related]  

  • 62. Effect of oral proguanil on human lymphocyte proliferation.
    Bygbjerg IC; Flachs H
    Eur J Clin Pharmacol; 1986; 30(2):249-51. PubMed ID: 3709655
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High-performance liquid chromatography of proguanil, cycloguanil and 4-chlorophenylbiguanide using hydrophobic pairing ion and its application to serum assay.
    Moody RR; Selkirk AB; Taylor RB
    J Chromatogr; 1980 Jun; 182(3-4):359-67. PubMed ID: 7391178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of proguanil interaction on bioavailability of cloxacillin.
    Babalola CP; Iwheye GB; Olaniyi AA
    J Clin Pharm Ther; 2002 Dec; 27(6):461-4. PubMed ID: 12472986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Simultaneous measurement of proguanil and cycloguanil in human plasma by high-performance liquid chromatography.
    Edstein MD
    J Chromatogr; 1986 Jul; 380(1):184-9. PubMed ID: 3745382
    [No Abstract]   [Full Text] [Related]  

  • 66. LABORATORY STUDIES ON THE REPOSITORY ANTIMALARIAL ACTIVITY OF 4,4'-DIACETYLAMINODIPHENYLSULFONE, ALONE AND MIXED WITH CYCLOGUANIL PAMOATE (CI-501).
    THOMPSON PE; OLSZEWSKI B; WAITZ JA
    Am J Trop Med Hyg; 1965 May; 14():343-53. PubMed ID: 14292737
    [No Abstract]   [Full Text] [Related]  

  • 67. Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine administration.
    Edstein MD; Veenendaal JR
    Trans R Soc Trop Med Hyg; 1987; 81(1):136-9. PubMed ID: 3445299
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of proguanil and cycloguanil on human lymphocytes in vitro.
    Bygbjerg IC
    Eur J Clin Pharmacol; 1985; 28(3):287-90. PubMed ID: 3874067
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-performance liquid chromatographic method for the determination of proguanil and cycloguanil in biological fluids.
    Kelly JA; Fletcher KA
    J Chromatogr; 1986 Sep; 381(2):464-71. PubMed ID: 3760104
    [No Abstract]   [Full Text] [Related]  

  • 70. Antimalarial activities of triazine metabolites of chlorguanide and dichlorguanide.
    SCHMIDT LH; LOO TL; FRADKIN R; HUGHES HB
    Proc Soc Exp Biol Med; 1952 Jun; 80(2):367-70. PubMed ID: 14949053
    [No Abstract]   [Full Text] [Related]  

  • 71. Active transport of tertiary amine compounds into bile.
    Nayak PK; Schanker LS
    Am J Physiol; 1969 Dec; 217(6):1639-43. PubMed ID: 5353038
    [No Abstract]   [Full Text] [Related]  

  • 72. Transport and binding of chloroguanide-triazine by rat liver slices.
    Gigon PL; Nayak PK; Schanker LS
    Proc Soc Exp Biol Med; 1969 Dec; 132(3):1103-9. PubMed ID: 5360987
    [No Abstract]   [Full Text] [Related]  

  • 73. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.
    Nguyen AT; Curtis KM; Tepper NK; Kortsmit K; Brittain AW; Snyder EM; Cohen MA; Zapata LB; Whiteman MK;
    MMWR Recomm Rep; 2024 Aug; 73(4):1-126. PubMed ID: 39106314
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Physiologic Changes During Pregnancy and Impact on Small-Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response.
    Eke AC; Gebreyohannes RD; Fernandes MFS; Pillai VC
    J Clin Pharmacol; 2023 Jun; 63 Suppl 1(Suppl 1):S34-S50. PubMed ID: 37317492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design Considerations for Pharmacokinetic Studies During Pregnancy.
    Stika CS; Hebert MF
    J Clin Pharmacol; 2023 Jun; 63 Suppl 1(Suppl 1):S126-S136. PubMed ID: 37317491
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure.
    Hudson RE; Metz TD; Ward RM; McKnite AM; Enioutina EY; Sherwin CM; Watt KM; Job KM
    Front Pharmacol; 2023; 14():1111601. PubMed ID: 37033628
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications.
    Poweleit EA; Cinibulk MA; Novotny SA; Wagner-Schuman M; Ramsey LB; Strawn JR
    Front Pharmacol; 2022; 13():833217. PubMed ID: 35281909
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sex-Biased Expression of Pharmacogenes across Human Tissues.
    Idda ML; Campesi I; Fiorito G; Vecchietti A; Urru SAM; Solinas MG; Franconi F; Floris M
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sources of Interindividual Variability.
    Lin YS; Thummel KE; Thompson BD; Totah RA; Cho CW
    Methods Mol Biol; 2021; 2342():481-550. PubMed ID: 34272705
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy.
    Hippman C; Slomp C; Morris E; Batallones R; Inglis A; Carrion P; Brain U; Higginson M; Wright GEB; Balneaves LG; Ryan D; Nislow C; Ross CJD; Gaedigk A; Oberlander TF; Austin J
    Arch Womens Ment Health; 2022 Apr; 25(2):355-365. PubMed ID: 34231053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.